INDOMETHACIN (indomethacin) by Molecular Devices is cyclooxygenase inhibitors [moa]. First approved in 1984.
Drug data last refreshed 14h ago · AI intelligence enriched 6d ago
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce inflammation, pain, and fever. It is an oral capsule formulation approved since 1984 for various inflammatory and pain conditions. The drug treats patients across multiple therapeutic areas requiring anti-inflammatory or analgesic effects.
Product is in late lifecycle stage with moderate competitive pressure (30), indicating declining team investment and focus on generic transition management.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Worked on INDOMETHACIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on indomethacin offers limited career advancement in a declining product lifecycle, with opportunities primarily in operations, manufacturing, and cost-containment initiatives. This role suits professionals seeking to manage legacy product portfolios or transition into generic/biosimilar operations.